Home » Topics » Regulatory » EMA

EMA
RSS

Kamada receives scientific advice from EMA for phase III trial of inhaled AAT

July 11, 2018

EMA validates Clovis' application for Rubraca as maintenance treatment for recurrent ovarian cancer

July 6, 2018

Detection of NDMA in Zhejiang Huahai's valsartan leads to EMA review and product recall

July 6, 2018

EMA committee recommends marketing authorization for Veyvondi

July 2, 2018

CHMP adopts positive opinion for Yescarta

July 2, 2018

Kymriah granted positive CHMP opinion for the treatment of two aggressive blood cancers

July 2, 2018

Vyxeos receives positive CHMP opinion

July 2, 2018

EMA committee recommends approval of Cablivi for aTTP

June 29, 2018

CHMP adopts positive trend vote recommending the approval of the MAA for neratinib

June 27, 2018

EMA validates Giapreza MAA

June 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...